Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 505 across all filing types
Latest filing 2020-10-21 Regulatory Filings
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes updates on clinical trial progress and patient enrollment, which are 'Other Events' under Item 8.01. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is relatively short (3126 characters) and serves as a regulatory announcement of recent company events rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2020-10-21 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated September 8, 2020. The key content is the notification of the resignation of a senior officer, specifically the Chief Commercial Officer and Head of International. This type of filing is related to changes in the company's board or senior management. The document does not contain financial data or other report types but focuses on management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is 2911 characters, which is consistent with a typical 8-K filing for management changes.
2020-09-11 English
10-Q
Interim / Quarterly Report Q2 2020
2020-08-13 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 13, 2020, reporting the company's financial results for the quarter ended June 30, 2020. It includes a press release as an exhibit announcing these results. The text explicitly states that the information is furnished and not filed, and it is a brief announcement rather than a full financial report. The document length is 3742 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2020-08-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates that shareholders should know about. The content describes an update on a clinical trial's sample size re-estimation and related operational details, which is an event update rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial analysis. The document is about an event (trial update) and forward-looking statements, typical of an 8-K current report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-07-13 English
Regulatory Filings 2020
Regulatory Filings
2020-07-06 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.